

Chapter 71

Lipodystrophy

Abhimanyu Garg

REFERENCES

1. Garg A: Acquired and inherited lipodystrophies. *N Engl J Med* **350**:1220-1234, 2004
2. Garg A: Lipodystrophies. *Am J Med* **108**:143-152, 2000
3. Garg A, Misra A: Lipodystrophies: Rare disorders causing metabolic syndrome. *Endocrinol Metab Clin North Am* **33**:305-331, 2004
4. Garg A, Wilson R, Barnes R, et al: A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. *J Clin Endocrinol Metab* **84**:3390-3394, 1999
5. Agarwal AK et al: *AGPAT2* is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. *Nat Genet* **31**:21-23, 2002
6. Magre J et al: Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. *Nat Genet* **28**:365-370, 2001
7. Kim CA et al: Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. *J Clin Endocrinol Metab* **93**:1129-1134, 2008
8. Hayashi YK et al: Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. *J Clin Invest* **119**:2623-2633, 2009
9. Agarwal AK, Garg A: Congenital generalized lipodystrophy: Significance of triglyceride biosynthetic pathways. *Trends Endocrinol Metab* **14**:214-221, 2003
10. Szymanski KM et al: The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology. *Proc Natl Acad Sci U S A* **104**:20890-20895, 2007
11. Fei W et al: Fld1p, a functional homologue of human seipin, regulates the size of lipid droplets in yeast. *J Cell Biol* **180**:473-482, 2008
12. Payne VA et al: The human lipodystrophy gene BSCL2/seipin may be essential for normal adipocyte differentiation. *Diabetes* **57**:2055-2060, 2008
13. Agarwal AK et al: Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. *J Clin Endocrinol Metab* **88**:4840-4847, 2003
14. Van Maldergem L et al: Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. *J Med Genet* **39**:722-733, 2002
15. Fleckenstein JL et al: The skeleton in congenital, generalized lipodystrophy: Evaluation using whole-body radiographic surveys, magnetic resonance imaging and technetium-99m bone scintigraphy. *Skeletal Radiol* **21**:381-386, 1992
16. Simha V, Garg A: Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the *AGPAT2* or seipin genes. *J Clin Endocrinol Metab* **88**:5433-5437, 2003
17. Rajab A et al: Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. *PLoS Genet* **6**:e1000874, 2010
18. Shastry S et al: Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations. *AM J Med Genet* **152A**(9):2245-2253, 2010
19. Cao H, Hegele RA: Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. *Hum Mol Genet* **9**:109-112, 2000
20. Shackleton S et al: LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. *Nat Genet* **24**:153-156, 2000
21. Speckman RA et al: Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C. *Am J Hum Genet* **66**:1192-1198, 2000
22. Peters JM et al: Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22. *Nat Genet* **18**:292-295, 1998
23. Agarwal AK, Garg A: A novel heterozygous mutation in peroxisome proliferator-activated receptor-g gene in a patient with familial partial lipodystrophy. *J Clin Endocrinol Metab* **87**:408-411, 2002

24. Hegele RA et al: PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. *Diabetes* 51:3586-3590, 2002
25. Semple RK, Chatterjee VK, O'Rahilly S: PPAR gamma and human metabolic disease. *J Clin Invest* 116:581-589, 2006
26. George S et al: A family with severe insulin resistance and diabetes due to a mutation in AKT2. *Science* 304:1325-1328, 2004
27. Gandotra S et al: Perilipin deficiency and autosomal dominant partial lipodystrophy. *N Engl J Med* 364:740-748, 2011
28. Dunnigan MG et al: Familial lipoatrophic diabetes with dominant transmission. A new syndrome. *Q J Med* 43:33-48, 1974
29. Garg A, Peshock RM, Fleckenstein JL: Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). *J Clin Endocrinol Metab* 84:170-174, 1999
30. Garg A. Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). *J Clin Endocrinol Metab* 85:1776-1782, 2000
31. Garg A, Speckman RA, Bowcock AM: Multisystem dystrophy syndrome due to novel missense mutations in the amino-terminal head and alpha-helical rod domains of the lamin A/C gene. *Am J Med* 112:549-555, 2002
32. Garg A et al: Phenotypic heterogeneity in patients with familial partial lipodystrophy (Dunnigan variety) related to the site of mis-sense mutations in Lamin A/C (LMNA) gene. *J Clin Endocrinol Metab* 86:59-65, 2001
33. Novelli G et al: Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. *Am J Hum Genet* 71:426-431, 2002
34. Agarwal AK et al: Zinc metalloproteinase, ZMP-STE24, is mutated in mandibuloacral dysplasia. *Hum Mol Genet* 12:1995-2001, 2003
35. Simha V, Garg A: Body fat distribution and metabolic derangements in patients with familial partial lipodystrophy associated with mandibuloacral dysplasia. *J Clin Endocrinol Metab* 87:776-785, 2002
36. Simha V et al: Genetic and phenotypic heterogeneity in patients with mandibuloacral dysplasia-associated lipodystrophy. *J Clin Endocrinol Metab* 88:2821-2824, 2003
37. Agarwal AK et al: Focal segmental glomerulosclerosis in patients with mandibuloacral dysplasia due to zinc metalloproteinase deficiency. *J Investig Med* 54:208-213, 2006
38. Ahmad Z et al: Early onset mandibuloacral dysplasia due to compound heterozygous mutations in ZMPSTE24. *Am J Med Genet* 152A(11):2703-2710, 2010
39. Rubio-Cabezas O et al: Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEA. *EMBO Mol Med* 1:280-287, 2009
40. Garg A et al: Atypical progeroid syndrome due to heterozygous missense LMNA mutations. *J Clin Endocrinol Metab* 94:4971-4983, 2009
41. Merideth MA et al: Phenotype and course of Hutchinson-Gilford progeria syndrome. *N Engl J Med* 358:592-604, 2008
42. Agarwal AK et al. PSMB8 encoding the β 5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. *Am J Hum Genet* 87:866-872, 2010
43. Liu et al. Mutations in PSMB8 cause CANDLE syndrome and evidence of genetic and phenotypic heterogeneity. *Arthritis Rheum*. In press, 2011
- 44a. Kitamura A, et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. *J Clin Invest*. 2011 Oct 3;121(10):4150-60
- 44b. Arima K et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. *Proceedings of the National Academy of Sciences of the United States of America*. *Proc Natl Acad Sci U S A* 2011 Sep 6;108(36):14914-9
- 44c. Rivett, A.J., and Hearn, A.R. (2004). Proteasome function in antigen presentation: Immunoproteasome complexes, peptide production, and interactions with viral proteins. *Curr. Protein Pept. Sci.* 5,153-161
45. Shastry S et al: A novel syndrome of mandibular hypoplasia, deafness and progeroid features associated with lipodystrophy, undescended testes and male hypogonadism. *J Clin Endocrinol Metab* 95(10):E192- E197, 2010 [Epub Jul 14, 2010]
46. Torrelo et al. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature. *J Am Acad Dermatol* 62:489-95, 2010
47. Garg A et al: An autosomal recessive syndrome of joint contractures, muscular atrophy, microcytic anemia, and panniculitis-associated lipodystrophy. *J Clin Endocrinol Metab* 95(9):E58-E63, 2010
48. Sensenbrenner JA, Hussels IE, Levin LS: CC – A low birthweight syndrome, Rieger syndrome. *Birth Defects* 11:423-426, 1975

49. Gorlin RJ et al: Rieger anomaly and growth retardation (The S-H-O-R-T Syndrome). *Birth Defects* 11:46-48, 1975
50. O'Neill B et al: Body fat distribution and metabolic variables in patients with neonatal progeroid syndrome. *Am J Med Genet A* 143:1421-1430, 2007
51. Misra A, Peethambaram A, Garg A: Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: Report of 35 cases and review of the literature. *Medicine (Baltimore)* 83:18-34, 2004
52. Misra A, Garg A: Clinical features and metabolic derangements in acquired generalized lipodystrophy: Case reports and review of the literature. *Medicine* 82:129-146, 2003
53. Chen D, Misra A, Garg A: Lipodystrophy in human immunodeficiency virus-infected patients. *J Clin Endocrinol Metab* 87:4845-4856, 2002
54. Mathieson PW et al: Complement-mediated adipocyte lysis by nephritic factor sera. *J Exper Med* 177:1827-1831, 1993
55. Hudon SE et al: HIV-protease inhibitors block the enzymatic activity of purified Step 24. *Biochem Biophys Res Commun* 374:365-368, 2008
56. Bastard JP et al: Association between altered expression of adipogenic factor SREBP1 in lipotrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. *Lancet* 359:1026-1031, 2002
57. Murata H, Hruz PW, Mueckler M: The mechanism of insulin resistance caused by HIV protease inhibitor therapy. *J Biol Chem* 275:20251-20254, 2000
58. Carr A et al: A syndrome of lipotrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome. *AIDS* 14:F25-F32, 2000
59. Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. *N Engl J Med* 352:48-62, 2005
60. Haque WA et al: Serum adiponectin and leptin levels in patients with lipodystrophies. *J Clin Endocrinol Metab* 87:2395-2398, 2002
61. Hegele RA: Premature atherosclerosis associated with monogenic insulin resistance. *Circulation* 103:2225-2229, 2001
62. Hennekam RC: Hutchinson-Gilford progeria syndrome: Review of the phenotype. *Am J Med Genet A* 140:2603-2624, 2006
63. Agarwal AK et al: Severe mandibuloacral dysplasia-associated lipodystrophy and progeria in a young girl with a novel homozygous Arg527Cys LMNA mutation. *J Clin Endocrinol Metab* 93:4617-4623, 2008
64. Sturm LP et al: A systematic review of permanent and semipermanent dermal fillers for HIV-associated facial lipodystrophy. *AIDS Patient Care STDS* 23:699-714, 2009
65. Arioglu E et al: Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. *Ann Intern Med* 133:263-274, 2000
66. Savage DB et al: Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-g. *Diabetes* 52:910-917, 2003
67. Oral EA et al: Leptin-replacement therapy for lipodystrophy. *N Engl J Med* 346:570-578, 2002
68. Simha V et al: Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. *Diabetes Care* 26:30-35, 2003
69. Park JY et al: Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. *Metabolism* 56:508-516, 2007
70. Carr A et al: HIV protease inhibitor substitution in patients with lipodystrophy: A randomized, controlled, open-label, multicentre study. *AIDS* 15:1811-1822, 2001

